Prediagnostic Allostatic Load as a Predictor of Poorly Differentiated and Larger Sized Breast Cancers among Black Women in the Women's Circle of Health Follow-Up Study.
Adult
Black or African American
/ statistics & numerical data
Aged
Allostasis
Body Mass Index
Breast Neoplasms
/ ethnology
Diabetes Mellitus
/ physiopathology
Female
Follow-Up Studies
Humans
Hypercholesterolemia
/ physiopathology
Hypertension
/ physiopathology
Middle Aged
Neoplasm Grading
Neoplasm Staging
Risk Factors
Tumor Burden
Waist Circumference
Young Adult
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
20
06
2019
revised:
16
09
2019
accepted:
30
10
2019
pubmed:
14
11
2019
medline:
25
9
2020
entrez:
14
11
2019
Statut:
ppublish
Résumé
Few studies have empirically tested the association of allostatic load (AL) with breast cancer clinicopathology. The aim of this study was to examine the association of AL, measured using relevant biomarkers recorded in medical records before breast cancer diagnosis, with unfavorable tumor clinicopathologic features among Black women. In a sample of 409 Black women with nonmetastatic breast cancer who are enrolled in the Women's Circle of Health Follow-Up Study, we estimated prediagnostic AL using two measures: AL measure 1 [lipid profile-based-assessed by systolic and diastolic blood pressure (SBP, DBP), high-density lipoprotein, low-density lipoprotein, total cholesterol, triglycerides, and glucose levels; waist circumference; and use of diabetes, hypertension, or hypercholesterolemia medication] and AL measure 2 (inflammatory index-based-assessed by SBP, DBP, glucose, and albumin levels; estimated glomerular filtration rate; body mass index; waist circumference; and use of medications previously described). We used Cohen's statistic to assess agreement between the two AL measures and multivariable logistic models to assess the associations of interest. AL measures 1 and 2 moderately agreed ( Elevated prediagnostic AL might contribute to more unfavorable breast cancer clinicopathology. Addressing elevated prediagnostic levels of AL has potentially important clinical implications.
Sections du résumé
BACKGROUND
Few studies have empirically tested the association of allostatic load (AL) with breast cancer clinicopathology. The aim of this study was to examine the association of AL, measured using relevant biomarkers recorded in medical records before breast cancer diagnosis, with unfavorable tumor clinicopathologic features among Black women.
METHODS
In a sample of 409 Black women with nonmetastatic breast cancer who are enrolled in the Women's Circle of Health Follow-Up Study, we estimated prediagnostic AL using two measures: AL measure 1 [lipid profile-based-assessed by systolic and diastolic blood pressure (SBP, DBP), high-density lipoprotein, low-density lipoprotein, total cholesterol, triglycerides, and glucose levels; waist circumference; and use of diabetes, hypertension, or hypercholesterolemia medication] and AL measure 2 (inflammatory index-based-assessed by SBP, DBP, glucose, and albumin levels; estimated glomerular filtration rate; body mass index; waist circumference; and use of medications previously described). We used Cohen's statistic to assess agreement between the two AL measures and multivariable logistic models to assess the associations of interest.
RESULTS
AL measures 1 and 2 moderately agreed (
CONCLUSIONS
Elevated prediagnostic AL might contribute to more unfavorable breast cancer clinicopathology.
IMPACT
Addressing elevated prediagnostic levels of AL has potentially important clinical implications.
Identifiants
pubmed: 31719063
pii: 1055-9965.EPI-19-0712
doi: 10.1158/1055-9965.EPI-19-0712
pmc: PMC6954339
mid: NIHMS1541924
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
216-224Subventions
Organisme : NCI NIH HHS
ID : K01 CA193527
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA151135
Pays : United States
Organisme : NIMHD NIH HHS
ID : K99 MD013300
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA222158
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201300021C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA185623
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA100598
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA172722
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201200021I
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Eur J Pharmacol. 2008 Apr 7;583(2-3):174-85
pubmed: 18282566
Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):524-31
pubmed: 25006187
Lancet. 2017 Apr 8;389(10077):1453-1463
pubmed: 28402827
JAMA Surg. 2017 May 1;152(5):485-493
pubmed: 28355428
Soc Sci Med. 2005 Oct;61(7):1576-96
pubmed: 16005789
J Natl Med Assoc. 2012 Jan-Feb;104(1-2):89-95
pubmed: 22708252
Ann N Y Acad Sci. 1999;896:262-77
pubmed: 10681903
SSM Popul Health. 2018 Jul 10;5:227-238
pubmed: 30094318
Biol Res Nurs. 2016 Oct;18(5):521-30
pubmed: 27118148
Am J Hum Biol. 2016 Sep 10;28(5):627-35
pubmed: 26877153
J Clin Oncol. 2009 Jul 20;27(21):3437-44
pubmed: 19470939
Soc Sci Med. 2012 Jan;74(1):75-83
pubmed: 22115943
Am J Public Health. 2012 Sep;102(9):1706-14
pubmed: 22873478
J Coll Physicians Surg Pak. 2009 Apr;19(4):207-10
pubmed: 19356332
Ann N Y Acad Sci. 2010 Feb;1186:223-39
pubmed: 20201875
Nat Rev Cancer. 2006 Mar;6(3):240-8
pubmed: 16498446
Am J Public Health. 2015 Jul;105 Suppl 3:S446-8
pubmed: 25905842
Ann Oncol. 2008 Sep;19 Suppl 7:vii86-90
pubmed: 18790986
J Cancer Surviv. 2018 Aug;12(4):460-468
pubmed: 29536415
BMC Cancer. 2013 Oct 14;13:475
pubmed: 24118876
Biofactors. 2014 Jan-Feb;40(1):1-12
pubmed: 23857944
Ethn Dis. 1992 Summer;2(3):207-21
pubmed: 1467758
Cancer. 2016 Jul 15;122(14):2138-49
pubmed: 26930024
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Endocr Relat Cancer. 2009 Dec;16(4):1103-23
pubmed: 19620249
Front Public Health. 2016 Nov 25;4:265
pubmed: 27933289
Hum Nat. 2010 Mar 10;21(1):19-38
pubmed: 20436780
CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42
pubmed: 26513636
Ann N Y Acad Sci. 1999;896:30-47
pubmed: 10681886
J Urban Health. 2019 Mar;96(Suppl 1):50-56
pubmed: 30488361
Cancer Epidemiol. 2014 Apr;38(2):118-23
pubmed: 24602836
J Womens Health (Larchmt). 2011 Apr;20(4):575-83
pubmed: 21428732
Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005284
pubmed: 30909729
Biol Res Nurs. 2012 Oct;14(4):311-46
pubmed: 23007870
Ann N Y Acad Sci. 1998 May 1;840:33-44
pubmed: 9629234
J Racial Ethn Health Disparities. 2017 Jun;4(3):455-461
pubmed: 27352114
J Urban Health. 2019 Mar;96(Suppl 1):3-11
pubmed: 30671711
Medicine (Baltimore). 2017 Oct;96(43):e8369
pubmed: 29069027
Arch Intern Med. 1997 Oct 27;157(19):2259-68
pubmed: 9343003
CA Cancer J Clin. 2019 May;69(3):211-233
pubmed: 30762872
Breast Cancer Res Treat. 2017 Aug;164(3):537-555
pubmed: 28503723
Am J Public Health. 2006 May;96(5):826-33
pubmed: 16380565
Epidemiology. 2016 Jan;27(1):6-13
pubmed: 26414938
Psychooncology. 2013 Mar;22(3):621-8
pubmed: 22290849
Am J Med Sci. 2003 Jun;325(6):315-31
pubmed: 12811228
Soc Sci Med. 2002 May;54(10):1589-99
pubmed: 12061489
J Cancer Surviv. 2014 Jun;8(2):312-8
pubmed: 24473830
AIMS Public Health. 2017;4(5):526-556
pubmed: 29333472